LYEL
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma, Inc. (LYEL) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (F). The rating has held at D+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | F (0.0) | D- (0.9) | C (2.4) | C- (2.1) | C+ (2.6) | D+ (1.6) |
| 2026-11-06 | F (0.0) | D (1.3) | C (2.4) | C- (1.9) | C+ (2.7) | D+ (1.7) |
| 2026-10-30 | F (0.0) | D (1.3) | C (2.4) | D+ (1.7) | C+ (2.7) | D+ (1.6) |
| 2026-10-23 | F (0.0) | D (1.3) | C (2.4) | D (1.4) | C+ (2.6) | D+ (1.6) |
| 2026-10-16 | F (0.0) | D (1.3) | C (2.4) | D (1.3) | C+ (2.6) | D+ (1.5) |